Современные подходы к терапии АНЦА-ассоциированных системных васкулитов


П.И. Новиков, С.В. Моисеев, Н.М. Буланов, Е.А. Макаров

Клиника нефрологии, внутренних и профессиональных болезней им. Е.М. Тареева, УКБ № 3, Первый МГМУ им. И.М. Сеченова; Кафедра внутренних, профессиональных болезней и пульмонологии МПФ, Первый МГМУ им. И.М. Сеченова, Москва; Кафедра внутренних болезней ФФМ МГУ им. М.В. Ломоносова, Москва
Представлены современные терапевтические стратегии, применяющиеся при АНЦА-ассоциированных системных васкулитах, в т.ч. подходы к их выбору в зависимости от нозологической формы, распространенности и тяжести органных поражений. Представлены результаты основных контролируемых клинических исследований. Подробно обсуждены перспективы применения таргетных биологических препаратов.

Литература



  1. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides // Arthritis Rheum. – 2013. – Vol. 65(1). – P. 1–11.

  2. Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов. // Клиническая фармакология и терапия. – 2013. – № 1. – C. 70–74.

  3. Fauci A.S., Haynes B.F., Katz P. et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years // Ann Intern Med. – 1983. – Vol. 98(1). – P. 76–85.

  4. Furuta S., Jayne D. Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis // Curr Opin Rheumatol. – 2014. – Vol. 26(1). – P. 1–6.

  5. de Groot K., Harper L., Jayne D.R. et al: EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial // Ann Intern Med. – 2009. – Vol. 19;150(10). – P. 670–680.

  6. Jayne D., Rasmussen N., Andrassy K. et al: European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies // N Engl J Med. – 2003. – Vol. 3;349(1). – P. 36–44.

  7. Schönermarck U., Gross W.L., de Groot K. Treatment of ANCA-associated vasculitis // Nat Rev Nephrol. – 2014. – Vol. 10(1). – P. 25–36.

  8. Hellmich B., Flossmann O., Gross W.L. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis // Ann Rheum Dis. – 2007. – Vol. 66(5). – P. 605–17.

  9. Mukhtyar C., Guillevin L., Cid M.C. et al: European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis // Ann Rheum Dis. – 2009. – Vol. 68(3). – P. 310–7.

  10. Lapraik C., Watts R., Bacon P. et al: BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis // Rheumatology (Oxford). – 2007. – Vol. 46(10). – P. 1615–1616.

  11. Stegeman C.A., Tervaert J.W., de Jong P.E. et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group // N Engl J Med. – 1996. – Vol. 4;335(1).– P. 16–20.

  12. De Groot K., Rasmussen N., Bacon P.A. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2005. – Vol. 52(8). – P. 2461–2469.

  13. Stone J.H., Merkel P.A., Spiera R. et al: RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis // N Engl J Med. – 2010. – Vol. 15;363(3). – P. 221–232.

  14. Jones R.B., Tervaert J.W., Hauser T. et al: European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis // N Engl J Med. – 2010. – Vol. 15;363(3). – P. 211–220.

  15. Jayne D.R., Gaskin G., Rasmussen N. et al: European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis // J Am Soc Nephrol. – 2007. – Vol. 18(7). – P. 2180–2188.

  16. Holle J.U., Dubrau C., Herlyn K. et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations // Ann Rheum Dis. – 2012. – Vol. 71(3). – P. 327–333.

  17. Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity // QJM. – 2000. – Vol. 93(7). – P. 433–439.

  18. Lamprecht P., Voswinkel J., Lilienthal T. et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis // Rheumatology (Oxford). – 2002. – Vol. 41(11). – P. 1303–1307.

  19. Joy M.S., Hogan S.L., Jennette J.C. et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis // Nephrol Dial Transplant. – 2005. – Vol. 20(12). – P. 2725–32.

  20. Birck R., Warnatz K., Lorenz H.M. et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy // J Am Soc Nephrol. – 2003. – Vol. 14(2). – P. 440–7.

  21. Schmitt W.H., Hagen E.C., Neumann I. et al: European Vasculitis Study Group. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients // Kidney Int. – 2004. – Vol. 65(4). – P. 1440–8.

  22. Pagnoux C., Mahr A., Hamidou M.A. et al: French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis // N Engl J Med. – 2008. – Vol. 25;359(26). – P. 2790–803.

  23. Metzler C., Fink C., Lamprecht P. et al. Maintenance of remission with leflunomide in Wegener's granulomatosis // Rheumatology (Oxford). – 2004. – Vol. 43(3). – P. 315–320.

  24. Zycinska K., Wardyn K.A., Zielonka T.M. et al. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement // Eur J Med Res. – 2009. – Vol. 7;14 Suppl 4. – P. 265–267.

  25. Новиков П.И. Классификация и номенклатура системных васкулитов – международный опыт в исторической перспективе. // Клиническая фармакология и терапия. – 2013. – № 4. – C. 57–64.

  26. Бекетова Т.В. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения // Научно-практическая ревматолология. – 2012. – № 6. – C. 19–28.

  27. Захарова Е.В., Яковлев В.Н., Виноградова О.В. и др. ANCA-ассоциированныe васкулиты с поражением легких и почек: клинико-морфологическая характеристика, лечение, исходы. // Клиническая медицина. – 2013. – № 7. – С. 38–43.

  28. Pagnoux C., Quéméneur T., Ninet J. et al. FVSG Treatment of systemic necrotizing vasculitides in patients ≥ 65 years old: Results of the multicenter randomized CORTAGE trial Presse Med. – 2013. – Vol. 42. – P. 679–80.

  29. Jones R., Harper L., Ballarin J. et al. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group Presse Med. – 2013. – Vol. 42. – P. 678–9.

  30. Hiemstra T.F., Walsh M., Mahr A. et al: European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial // JAMA. – 2010. – Vol. 1;304(21). – P. 2381–2388.

  31. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis // N Engl J Med. – 2005. – Vol. 27;352(4). – P. 351–361.

  32. Walsh M., Flossmann O., Berden A. et al: European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2012. – Vol. 64(2). – P. 542–548.

  33. Кузнецова Е.И., Стрижаков Л.А., Новиков П.И. и др. Атеросклероз при АНЦА-ассоциированных системных васкулитах // Научно-практическая ревматология. – 2012. – № 3. – С. 92–96.

  34. Кузнецова Е.И., Моисеев С.В., Новиков П.И. и др. Субклинический атеросклероз периферических артерий у больных гранулематозом с полиангиитом (Вегенера) // Клиническая фармакология и терапия. – 2013. – № 4. – С. 36–41.

  35. Walsh M., Merkel P.A., Mahr A. et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis // Arthritis Care Res (Hoboken). – 2010. – Vol. 62(8). – P. 1166–1173.

  36. Voswinkel J., Müller A., Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production // Ann N Y Acad Sci. – 2005. – Vol. 1051. – P. 12–19.

  37. Voswinkel J., Mueller A., Kraemer J.A. et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions // Ann Rheum Dis. – 2006. – Vol. 65(7). – P. 859–864.

  38. Krumbholz M., Specks U., Wick M. et al. BAFF is elevated in serum of patients with Wegener's granulomatosis // J Autoimmun. – 2005. – Vol. 25(4). – P. 298–302.

  39. Cupps T.R., Edgar L.C., Fauci A.S. Suppression of human B lymphocyte function by cyclophosphamide // J Immunol. – 1982. – Vol. 128(6). – P. 2453–2457.

  40. Specks U., Fervenza F.C., McDonald T.J. et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy // Arthritis Rheum. – 2001. – Vol. 44(12). – P. 2836–40.

  41. Keogh K.A., Wylam M.E., Stone J.H. et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2005. – Vol. 52(1). – P. 262–268.

  42. Keogh K.A., Ytterberg S.R., Fervenza F.C. et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial // Am J Respir Crit Care Med. – 2006. – Vol. 15;173(2). – P. 180–187.

  43. Мухин Н.А., Семенкова Е.Н., Кривошеев О.Г. и др. Применение ритуксимаба при тяжелых АНЦА-ассоциированных системных васкулитах // Клиническая нефрология. – 2010. – № 2. – С. 40–45.

  44. Новиков П.И., Семенкова Е.Н., Кривошеев О.Г. Опыт использования моноклональных антител к рецепторам CD20 В-лимфоцитов (ритуксимаба) у больных с поражением почек при гранулематозе Вегенера. // Терапевтический архив. – 2011. – № 11. – С. 70–76.

  45. Мухин Н.А., Новиков П.И., Моисеев С.В. и др. Оценка краткосрочной эффективности и безопасности биологических препаратов при различных ревматических заболеваниях – опыт многопрофильного терапевтического стационара // Научно-практическая ревматология. – 2013. – № 2. – С. 138–144.

  46. Specks U., Merkel P.A., Seo P. et al: RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis // N Engl J Med. – 2013. – Vol. 1;369(5). – P. 417–427.

  47. Smith R.M., Jones R.B., Guerry M.J. et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2012. – Vol. 64(11). – P. 3760–3769.

  48. Rhee E.P., Laliberte K.A., Niles J.L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis // Clin J Am Soc Nephrol. – 2010. – Vol. 5(8). – |P. 1394–400.

  49. Charles P., Néel A., Tieulié N. et al; on behalf of the French Vasculitis Study Group. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients // Rheumatology (Oxford). – 2013 Nov 26. [Epub ahead of print]

  50. Charles P., Bienvenu B., Bonnotte B. et al: French Vasculitis Study Group. Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides // Presse Med. – 2013. – Vol. 42(10). – P. 1317–1330.

  51. Cartin-Ceba R., Golbin J.M., Keogh K.A. et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center // Arthritis Rheum. – 2012. – Vol. 64(11). – P. 3770–378.

  52. Charles P., Guillevin L. S3. Rituximab for ANCA-associated vasculitides: the French experience // Presse Med. – 2013. – Vol. 42(4 Pt 2). – P. 534–536.

  53. Wallace D.J., Kalunian K., Petri M.A. et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study // Ann Rheum Dis. – 2014. – Vol. 73(1). – P. 183–90.

  54. Wallace D.J., Gordon C., Strand V. et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up // Rheumatology (Oxford). – 2013. – Vol. 52(7). – P. 1313–1322.

  55. Abdulahad W.H., Lamprecht P., Kallenberg C.G. T-helper cells as new players in ANCA-associated vasculitides // Arthritis Res Ther. – 2011. – Vol. 23;13(4). – P. 236.

  56. Berden A.E., Jones R.B., Erasmus D.D. et al; European Vasculitis Society. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy // J Am Soc Nephrol. – 2012. – Vol. 23(2). – P. 313–321.

  57. Langford C.A., Monach P.A., Specks U. et al: for the Vasculitis Clinical Research Consortium. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's) // Ann Rheum Dis. – 2013. Dec 9. doi: 10.1136/annrheumdis-2013-204164. [Epub ahead of print]

  58. Walsh M., Chaudhry A., Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H) // Ann Rheum Dis. – 2008. – Vol. 67(9). – P. 1322–1327.

  59. Xing G.Q., Chen M., Liu G. et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis // J Clin Immunol. – 2009. – Vol. 29(3). – P. 282–291.

  60. Xiao H., Schreiber A., Heeringa P. et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies // Am J Pathol. – 2007. – Vol. 170(1). – P. 52–64.

  61. Yuan J., Gou S.J., Huang J. et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis // Arthritis Res Ther. – 2012. – Vol. 12;14(3). – P. R140.

  62. Lúdvíksson B.R., Sneller M.C., Chua K.S. et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10 // J Immunol. – 1998. – Vol. 1;160(7). – P. 3602–3609.

  63. Bartolucci P., Ramanoelina J., Cohen P. et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients // Rheumatology (Oxford). – 2002. – Vol. 41(10). – P. 1126–3112.

  64. Stone J.H., Uhlfelder M.L., Hellmann D.B. et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety // Arthritis Rheum. – 2001. – Vol. 44(5). – P. 1149–1454.

  65. Laurino S., Chaudhry A., Booth A. et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement // Nephrol Dial Transplant. – 2010. – Vol. 25(10). – P. 3307–3314.

  66. Booth A., Harper L., Hammad T. et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis // J Am Soc Nephrol. – 2004. – Vol. 15(3). – P. 717–721.

  67. Muller Kobold A.C., van Wijk R.T., Franssen C.F. et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis // Clin Exp Rheumatol. – 1999. – Vol. 17(4). – P. 433–440.

  68. Sumida K., Ubara Y., Suwabe T. et al. Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody // Rheumatology (Oxford). – 2011. – Vol. 50(10). – P. 1928–1930.

  69. Bontscho J., Schreiber A., Manz R.A. et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis // J Am Soc Nephrol. – 2011. – Vol. 22(2). – P. 336–348.

  70. Fox D.A. Kinase inhibition--a new approach to the treatment of rheumatoid arthritis // N Engl J Med. – 2012. – Vol. 9;367(6). – P. 565–567.

  71. Жабина Е.С., Моисеев С.В., Новиков П.И. и др. Эозинофильный гранулематоз с полиангиитом (Черга-Страусс): клинические варианты, диагностика и лечение. // Клиническая фармакология и терапия. – 2013. – № 5. – С. 85–92.

  72. Ribi C., Cohen P., Pagnoux C. et al: French Vasculitis Study Group. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients // Arthritis Rheum. – 2008. – Vol. 58(2). – P. 586–594.

  73. Pepper R.J., Fabre M.A., Pavesio C. et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production // Rheumatology (Oxford). – 2008. – Vol. 47(7). – P. 1104–1105.

  74. Cartin-Ceba R., Keogh K.A., Specks U. et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement // Nephrol Dial Transplant. – 2011. – Vol. 26(9). – P. 2865–71.

  75. Thiel J., Hässler F., Salzer U. et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) // Arthritis Res Ther. – 2013. – Vol. 24;15(5). – P. R133.

  76. Bouldouyre M.A., Cohen P., Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome // Ann Rheum Dis. – 2009. – Vol. 68(4). – P. 606.

  77. Kim S., Marigowda G., Oren E. et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome // J Allergy Clin Immunol. – 2010. – Vol. 125(6). – P. 1336–43.

  78. Moosig F., Gross W.L., Herrmann K. et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome // Ann Intern Med. – 2011. – Vol. 6;155(5). – P. 341–3.

  79. Metzler C., Csernok E., Gross W.L. et al. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study // Clin Exp Rheumatol. – 2010. – Vol. 28(1 Suppl 57). – P. 24–30.

  80. Silva F., Specks U., Kalra S. et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-a prospective, open-label pilot trial // Clin J Am Soc Nephrol. – 2010. – Vol. 5(3). – P. 445–453.

  81. Hu W., Liu C., Xie H. et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement // Nephrol Dial Transplant. – 2008. – Vol. 23(4). – P. 1307–1312.

  82. Walsh M., Catapano F., Szpirt W. et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis // Am J Kidney Dis. – 2011. – Vol. 57(4). – P. 566–574.

  83. Walsh M., Merkel P.A., Peh C.A. et al: PEXIVAS Investigators. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial // Trials. – 2013. – Vol. 14;14. – P. 73.

  84. Guo Z., Li X., Jiang L.Y. et al. Extracorporeal membrane oxygenation for the management of respiratory failure caused by diffuse alveolar hemorrhage // J Extra Corpor Technol. – 2009. – Vol. 41(1). – P. 37–40.

  85. Hasegawa M., Ohashi A., Kabutan N. et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients // Ther Apher Dial. – 2006. – Vol. 10(5). – P. 412–418.

  86. Gong D., Ji D., Xu B. et al. More selective removal of myeloperoxidase-anti-neutrophil cytoplasmic antibody from the circulation of patients with vasculitides using a novel double-filtration plasmapheresis therapy // Ther Apher Dial. – 2013. – Vol. 17(1). – P. 93–98.


Об авторах / Для корреспонденции


Новиков П.И. – заведующий ревматологическим отделением УКБ №3, ассистент кафедры внутренних профессиональных болезней и пульмонологии МПФ, Первый МГМУ им. И.М. Сеченова, к.м.н.
E-mail: novikov-pavel@mail.ru;
Моисеев С.В. – профессор кафедры внутренних, профессиональных болезней
и пульмонологии МПФ, Первый МГМУ им. И.М. Сеченова, профессор
кафедрывнутренних болезней ФФМ МГУ им. М.В. Ломоносова, д.м.н.;
Буланов Н.М. – аспирант кафедры внутренних, профессиональных болезней
и пульмонологии МПФ, Первый МГМУ им. И.М. Сеченова;
Макаров Е.А. – аспирант кафедры внутренних болезней ФФМ МГУ
им. М.В. Ломоносова


Похожие статьи


Бионика Медиа